Rethinking hypophosphatasia (HPP) and systemic impacts of deficient alkaline phosphatase activity

Hypophosphatasia (HPP) disrupts the body’s ecosystem through a deficiency in a key enzyme: alkaline phosphatase (ALP).¹

ALP deficiency, or low ALP, is most recognised for impacting the skeletal system, but we can rethink HPP by understanding that it has systemic, wide-reaching effects on muscles, the nervous system, mood, pain perception, and more.²  

In this short, animated video, explore: 

• The crucial role of ALP in bone mineralisation, muscle function, and neurotransmitter synthesis ^3,4,5,6,7 
• Clinical features of HPP, which can include pain, fatigue, poorly healing fractures, muscle weakness, headache, mood disorders, and sleep disturbance 
• Two common patient phenotypes of HPP: Pain and Bone 
• Why it’s time to rethink HPP by earlier recognition of HPP signs and symptoms, and impact of persistently low ALP levels ^5,8,9
  
  

Going to the joint ESPE-ESE congress? 
 

• Visit Alexion at Booth E19 and ask us about how we are rethinking HPP  
• Join Dr Leila Chaychi for a mini symposium to get straight to the source of hypophosphatasia. Sunday 11th May, 09:55, Room C4 
• Join Drs Agnès Linglart, Florian Barvencik, and Kathryn Dahir for a symposium covering early diagnosis to effective management: advances in lifelong care in hypophosphatasia. Monday 12th May, 16:15, Room C2

1.Khan AA, Josse R, Kannu P, et al. Osteoporos Int. 2019;30:1713-1722. 2.Khan AA, Brandi ML, Rush ET, et al. Osteoporos Int. 2023;35:431-438. 3.Sharma U, Pal D, Prasad R. Ind J Clin Biochem. 2014;29:269-278:1-8. 4.Khan AA et al. Osteoporosis Int 2024;35:431–8. 5.Rockman-Greenberg C. Pediatr Endocrinol Rev 2013;10(suppl 2):S380–8. 6.Linglart A, Biosse-Duplan M. Curr Osteoporos Rep 2016;14:95–105. 7.Reis FS, Lazaretti-Castro M. Arch Endocrinol Metab 2023;25;67(5):e000626. 8.Whyte MP. Ann N Y Acad Sci. 2010;1192:190-200. 9.Tournis S, et al. J Clin Med. 2021;10(23):5676

Now view 5 fact cards here to reveal key statistics and clinical insights on the diagnosis and disease burden of hypophosphatasia (HPP) in children and adults. Will they make you rethink HPP diagnosis and disease burden?